Video

Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC

Author(s):

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non—small cell lung cancer (NSCLC).

Pivotal trials in this area of research include the ALEX and J-ALEX studies, Mok explains. In the J-ALEX trial, an open-label phase III Japanese study, alectinib (Alecensa) improved progression-free survival (PFS) by 66% compared with crizotinib (Xalkori) as frontline therapy in patients with advanced or recurrent ALK-positive disease. In the global phase III ALEX trial, alectinib is being compared with crizotinib in chemotherapy-naïve patients with ALK-positive NSCLC.

Mok advises that researchers should wait for the global ALEX results before making treatment decisions, as there are major differences between J-ALEX and ALEX. The ALEX findings are expected to be presented in 2017, which should help practitioners determine whether crizotinib or alectinib is a more effective frontline treatment for patients with ALK-positive NSCLC.

<<<

View more from the 2016 International Lung Cancer Congress

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.